Multivariable analyses of TRM at 1 year by biomarker thresholds
| Marker∗ . | HR (95% CI) . | P value . |
|---|---|---|
| CXCL9 | ||
| Overall | 1.69 (0.62-4.61) | .30 |
| ≤10 y | — | — |
| >10 y | 1.94 (0.65-5.79) | .24 |
| IL1RL1 | ||
| Overall | 4.69 (1.76-12.5) | .002 |
| ≤10 y | 5.42 (0.56-52.0) | .14 |
| >10 y | 4.19 (1.4-12.5) | .01 |
| REG3α | ||
| Overall | 5.11 (2.31-11.3) | <.001 |
| ≤10 y | 1.88 (0.28-12.7) | .52 |
| >10 y | 10.6 (4.13-27.1) | <.001 |
| MMP3 | ||
| Overall | 4.62 (1.91-11.2) | <.001 |
| ≤10 y | 0.70 (0.07-7.11) | .77 |
| >10 y | 5.91 (1.94-17.9) | .002 |
| DKK3 | ||
| Overall | 3.95 (1.39-11.2) | .01 |
| ≤10 y | 0.88 (0.05-15.6) | .93 |
| >10 y | 5.71 (1.81-18.0) | .003 |
| sCD163 | ||
| Overall | 5.94 (2.18-16.2) | <.001 |
| ≤10 y | 6.51 (0.36-11.6) | .2 |
| >10 y | 8.04 (2.29-28.3) | .001 |
| Marker∗ . | HR (95% CI) . | P value . |
|---|---|---|
| CXCL9 | ||
| Overall | 1.69 (0.62-4.61) | .30 |
| ≤10 y | — | — |
| >10 y | 1.94 (0.65-5.79) | .24 |
| IL1RL1 | ||
| Overall | 4.69 (1.76-12.5) | .002 |
| ≤10 y | 5.42 (0.56-52.0) | .14 |
| >10 y | 4.19 (1.4-12.5) | .01 |
| REG3α | ||
| Overall | 5.11 (2.31-11.3) | <.001 |
| ≤10 y | 1.88 (0.28-12.7) | .52 |
| >10 y | 10.6 (4.13-27.1) | <.001 |
| MMP3 | ||
| Overall | 4.62 (1.91-11.2) | <.001 |
| ≤10 y | 0.70 (0.07-7.11) | .77 |
| >10 y | 5.91 (1.94-17.9) | .002 |
| DKK3 | ||
| Overall | 3.95 (1.39-11.2) | .01 |
| ≤10 y | 0.88 (0.05-15.6) | .93 |
| >10 y | 5.71 (1.81-18.0) | .003 |
| sCD163 | ||
| Overall | 5.94 (2.18-16.2) | <.001 |
| ≤10 y | 6.51 (0.36-11.6) | .2 |
| >10 y | 8.04 (2.29-28.3) | .001 |
Controlling for White/non-Hispanic (yes/no), malignant vs nonmalignant, graft source, GVHD prophylaxis, and ATG/alemtuzumab use. Sample sizes for models were overall, N = 294; ≤10 y, n = 124; >10 y, n = 170, except for models for DKK3 and sCD163 in which sample sizes were overall, N = 244; ≤10 y, n = 103; >10 y, n = 141.
Markers dichotomized at selected thresholds.